Ligand Pharmaceuticals Inc.  

(Public, NASDAQ:LGND)   Watch this stock  
Find more results for LGND
89.75
+0.83 (0.93%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 86.76 - 89.98
52 week 41.99 - 89.98
Open 88.92
Vol / Avg. 202,610.00/437,573.00
Mkt cap 1.76B
P/E 157.39
Div/yield     -
EPS 0.57
Shares 19.58M
Beta 1.13
Inst. own 112%
May 12, 2015
Ligand Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference - 6:40PM EDT - Add to calendar
May 11, 2015
Q1 2015 Ligand Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
May 11, 2015
Q1 2015 Ligand Pharmaceuticals Inc Earnings Call - 9:00AM EDT - Add to calendar
May 6, 2015
Ligand Pharmaceuticals Inc at Deutsche Bank Health Care Conference - 9:20AM EDT - Add to calendar
Mar 9, 2015
Ligand Pharmaceuticals Inc at ROTH Conference
Feb 24, 2015
Ligand Pharmaceuticals Inc at RBC Healthcare Conference
Feb 9, 2015
Ligand Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference
Feb 9, 2015
Q4 2014 Ligand Pharmaceuticals Inc Earnings Release
Feb 9, 2015
Q4 2014 Ligand Pharmaceuticals Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 29.27% 16.88%
Operating margin 41.90% 30.41%
EBITD margin - 36.27%
Return on average assets 10.18% 6.01%
Return on average equity 80.06% 31.67%
Employees 19 -
CDP Score - -

Address

Suite 200, 11119 North Torrey Pines Road
LA JOLLA, CA 92037
United States - Map
+1-858-5507500 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ligand Pharmaceuticals Incorporated is a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure. The Company�s technology CAPTISOL is a formulation technology that has enabled six products, including Onyx's Kyprolis and Baxter International's Nexterone, while partnering in several clinical-stage programs. The therapies in the Company�s development portfolio address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, immune (idiopathic) thrombocytopenic purpura, or ITP, muscle wasting, multiple myeloma, Alzheimer�s disease, dyslipidemia, diabetes, anemia, epilepsy, Focal Segmental Glomerulosclerosis, or FSGS and osteoporosis. The Company has potential revenue-generating programs, over 90 of which are fully-funded by its partners.

Officers and directors

John W. Kozarich Ph.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Matthew W. Foehr President, Chief Operating Officer
Age: 42
Bio & Compensation  - Reuters
John L. Higgins Chief Executive Officer, Director
Bio & Compensation  - Reuters
Nishan M. de Silva M.D. Chief Financial Officer, Vice President - Finance and Strategy
Age: 41
Bio & Compensation  - Reuters
Charles S. Berkman J.D. Vice President, General Counsel, Secretary
Age: 46
Bio & Compensation  - Reuters
Jason M. Aryeh Independent Director
Age: 46
Bio & Compensation  - Reuters
Todd C. Davis Independent Director
Age: 54
Bio & Compensation  - Reuters
David M. Knott Independent Director
Age: 70
Bio & Compensation  - Reuters
John L. LaMattina Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Sunil Patel Independent Director
Age: 43
Bio & Compensation  - Reuters